contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


lifecare-resubmits-application-for-first-in-human-clinical-study

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Lifecare is a Norwegian company operating in medical technology. The company specializes in research and development of solutions for diabetes. The microsensors are injected under the skin of the patient's wrist, and also function as a real-time update of the patient's glucose level. In addition, the technology provides an alarm sensor and access to historical data on the patient's glucose level. The company was established in 2006 and is headquartered in Bergen, Norway.

Lifecare

Bergen, Norway, 15 September 2025 – Lifecare ASA (LIFE), a MedTech company developing next generation of Continuous Glucose Monitoring (CGM) technology for diabetes management, today announces...

<div class="mfn-preamble"><p><strong>Bergen, Norway, 15 September 2025 – Lifecare ASA (LIFE), a MedTech company developing next generation of Continuous Glucose Monitoring (CGM) technology for diabetes management, today announces that it has resubmitted its application to the Norwegian Medical Products Agency (NOMA) for authorization to initiate the company’s first-in-human clinical study.</strong></p></div><div class="mfn-body"><p>As part of a normal regulatory process, NOMA has provided feedback to ensure that the study meets regulatory, scientific, and safety requirements. Lifecare has carefully addressed comments received from NOMA, based on our initial application. We have updated the documentation in line with the agency’s guidance, ensuring compliance with the latest regulatory requirements, and resubmitted the application.</p><p>The application covers the first-in-human pilot study with Lifecare’s proprietary CGM system consisting of an implantable sensor, software and read-out device. The study is designed to confirm safety, tolerability, and glucose measurement performance.</p><p>Lifecare expects that the&nbsp;initial approval from the Norwegian Regional Committee for Medical and Health Research Ethics (REK)&nbsp;will be reissued, as the committee has already granted approval subject only to minor documentation updates.</p><p>Lifecare’s CEO, Joacim Holter, comments:<br>“We welcome the feedback from NOMA, which has helped us strengthen our submission. The resubmission is an important forward step in our regulatory pathway and demonstrates our commitment to meeting the highest standards for patient safety and product quality. We remain on track with our strategy and timelines, and this is another milestone on our way to making our innovative sensor technology available to people with diabetes.”</p><p>This first-in-human study will pave the way for Lifecare’s pivotal CE-marking study, scheduled for 2026, and the planned European commercial launch in 2027.</p></div><div class="mfn-footer mfn-6f66f307be9c"><p><strong class="mfn-heading-1">About us</strong><br>Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring ("<strong>CGM</strong>") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.</p></div><div class="mfn-footer mfn-contacts mfn-742f7fc5e6f2"><p><strong class="mfn-heading-1">Contacts</strong><br>For further information, please contact:<br><br>Joacim Holter, CEO,  joacim.holter@lifecare.no, +47 40 05 90 40</p><p>Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42<br><br></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/5e979c6a-0ae7-4751-85e9-3d45d9f99b7b/lifecare-resubmits-application-for-first-in-human-clinical-study.pdf" class="mfn-generated mfn-primary">LIFECARE RESUBMITS APPLICATION FOR FIRST-IN-HUMAN CLINICAL STUDY</a></p></div>